The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2016 | Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes

Name: Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes
Uploaded: 2016-06-09T00:00:00.000Z
Duration: 4 min 2 s
Description: Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of treatment outcomes of 243 patients with 17p del CLL treated with ibrutinib at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

Jeffrey Jones • 9 Jun 2016

EHA 2016

Chronic Lymphocytic Leukemia Ibrutinib

Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of treatment outcomes of 243 patients with 17p del CLL treated with ibrutinib at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.